Heart Failure Clinical Trial

Intravascular Volume Expansion to Neuroendocrine-Renal Function Profiles in Chronic Heart Failure

Summary

Researchers are trying learn more about how the heart and blood volume interact in subjects with heart failure and how measuring blood volume may help them develop better ways of treating and managing heart failure patients.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Acute Decompensated Chronic Heart Failure, diagnosed clinically with volume overload by the primary Heart Failure provider or Emergency Department physician and admitted to hospital.
New York Hear Association functional class III-IVa with stage C or D Heart Failure with Left Ventricular Ejection Fraction <50%
Intended treatment plan with intravenous loop diuretic therapy during hospitalization
Meeting none of the Exclusion Criteria

Exclusion Criteria:

Age < 18 years
Having received any investigational drug or device within 30 days prior to entry into the study.
Clinically unstable patients (e.g. systolic blood pressure < 90 mmHg, ongoing requirement for vasopressors or mechanical circulatory support, or mechanical ventilation).
Hospitalization within three months prior to study for hemodialysis or an ongoing requirement for hemodialysis or ultrafiltration.
Prior organ transplantation or being on a waiting list for organ transplantation
Presence of cardiac conditions such as clinically significant cardiac valve stenosis, hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or primary arterial pulmonary hypertension (Group 1 PAH).
History of blood pressure > 190/115 mmHg or unexplained syncope within the past 3 months.
Symptomatic carotid artery disease, known critical carotid stenosis, or stroke within the past 3 months
Clinically significant intrinsic renal disease (eGFR <15 ml/min/1.72m2), renal artery stenosis, or history of fibromuscular dysplasia of the renal arteries
Baseline hemoglobin < 8.5 g/dl, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) that is five times or more the upper limit of normal or bilirubin three times or more the upper limit of normal
History of alcohol abuse within the past 6 months.

Study is for people with:

Heart Failure

Estimated Enrollment:

15

Study ID:

NCT04156854

Recruitment Status:

Completed

Sponsor:

Mayo Clinic

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Mayo Clinic in Rochester
Rochester Minnesota, 55905, United States

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Estimated Enrollment:

15

Study ID:

NCT04156854

Recruitment Status:

Completed

Sponsor:


Mayo Clinic

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.